Breaking news and analysis on the biotech industry — covering drug development, clinical trials, IPOs, M&A, and the companies pushing biopharma forward.
Kyorin Pharmaceutical is paying $12 million upfront for the Japan rights to Edesa Biotech’s anti-TLR4 antibody to treat acute respiratory distress syndrome.
